Dacomitinib versus erlotinib in patients with advanced-stage, previously treated non-small-cell lung cancer (ARCHER 1009): a randomised, double-blind, phase 3 trial
Background Dacomitinib is an irreversible pan-EGFR family tyrosine kinase inhibitor.
Findings from a phase 2 study in non-small cell lung cancer showed favourable efficacy for …
Findings from a phase 2 study in non-small cell lung cancer showed favourable efficacy for …
Dacomitinib as first-line treatment in patients with clinically or molecularly selected advanced non-small-cell lung cancer: a multicentre, open-label, phase 2 trial
Background Patients with EGFR-mutant non-small-cell lung cancer generally have a
progression-free survival of 9–13 months while being treated with the EGFR tyrosine-kinase …
progression-free survival of 9–13 months while being treated with the EGFR tyrosine-kinase …
Dacomitinib compared with placebo in pretreated patients with advanced or metastatic non-small-cell lung cancer (NCIC CTG BR. 26): a double-blind, randomised …
Background Dacomitinib is an irreversible pan-HER tyrosine-kinase inhibitor with preclinical
and clinical evidence of activity in non-small-cell lung cancer. We designed BR. 26 to assess …
and clinical evidence of activity in non-small-cell lung cancer. We designed BR. 26 to assess …
Randomized phase II study of dacomitinib (PF-00299804), an irreversible pan–human epidermal growth factor receptor inhibitor, versus erlotinib in patients with …
SS Ramalingam, F Blackhall, M Krzakowski… - Journal of Clinical …, 2012 - ascopubs.org
Purpose This randomized, open-label trial compared dacomitinib (PF-00299804), an
irreversible inhibitor of human epidermal growth factor receptors (EGFR)/HER1, HER2, and …
irreversible inhibitor of human epidermal growth factor receptors (EGFR)/HER1, HER2, and …
A phase 2 trial of dacomitinib (PF‐00299804), an oral, irreversible pan‐HER (human epidermal growth factor receptor) inhibitor, in patients with advanced non–small …
KL Reckamp, G Giaccone, DR Camidge, SM Gadgeel… - Cancer, 2014 - Wiley Online Library
BACKGROUND This phase 2 trial (ClinicalTrials. gov identifier NCT00548093) assessed the
efficacy, safety, and impact on health‐related quality of life of dacomitinib (PF‐00299804) …
efficacy, safety, and impact on health‐related quality of life of dacomitinib (PF‐00299804) …
Dacomitinib in the management of advanced non-small-cell lung cancer
SCM Lau, U Batra, TSK Mok, HH Loong - Drugs, 2019 - Springer
The use of targeted therapy in the management of epidermal growth factor receptor (EGFR)-
mutated non-small-cell lung cancer is an important milestone in the management of …
mutated non-small-cell lung cancer is an important milestone in the management of …
[HTML][HTML] Dacomitinib versus erlotinib in patients with EGFR-mutated advanced nonsmall-cell lung cancer (NSCLC): pooled subset analyses from two randomized trials
SS Ramalingam, K O'Byrne, M Boyer, T Mok… - Annals of …, 2016 - Elsevier
Background The irreversible epidermal growth factor receptor (EGFR) inhibitors have
demonstrated efficacy in NSCLC patients with activating EGFR mutations, but it is unknown …
demonstrated efficacy in NSCLC patients with activating EGFR mutations, but it is unknown …
Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label …
YL Wu, Y Cheng, X Zhou, KH Lee, K Nakagawa… - The Lancet …, 2017 - thelancet.com
Background Dacomitinib is a second-generation, irreversible EGFR tyrosine kinase inhibitor.
We compared its efficacy and safety with that of the reversible EGFR tyrosine kinase inhibitor …
We compared its efficacy and safety with that of the reversible EGFR tyrosine kinase inhibitor …
Clinical evaluation of dacomitinib for the treatment of metastatic non-small cell lung cancer (NSCLC): current perspectives
D Lavacchi, F Mazzoni, G Giaccone - Drug design, development …, 2019 - Taylor & Francis
Systemic treatment of advanced non-small cell lung cancer (NSCLC) has undergone
remarkable changes in the last decade, with the introduction of targeted therapies and …
remarkable changes in the last decade, with the introduction of targeted therapies and …
Updated overall survival in a randomized study comparing dacomitinib with gefitinib as first-line treatment in patients with advanced non-small-cell lung cancer and …
TS Mok, Y Cheng, X Zhou, KH Lee, K Nakagawa… - Drugs, 2021 - Springer
Background ARCHER 1050, an ongoing, randomized, open-label, phase III trial of
dacomitinib versus gefitinib in newly diagnosed patients with advanced non-small-cell lung …
dacomitinib versus gefitinib in newly diagnosed patients with advanced non-small-cell lung …
相关搜索
- erlotinib in patients lung cancer
- irreversible pan lung cancer
- egfr mutation lung cancer
- dacomitinib with gefitinib lung cancer
- randomized phase lung cancer
- receptor inhibitor lung cancer
- subset analyses lung cancer
- growth factor lung cancer
- overall survival lung cancer
- erlotinib in patients irreversible pan
- erlotinib in patients randomized phase
- erlotinib in patients receptor inhibitor
- erlotinib in patients subset analyses
- erlotinib in patients growth factor
- irreversible pan randomized phase
- irreversible pan receptor inhibitor